Trials / Completed
CompletedNCT00388440
Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore.
Phase IV Open Study to Assess the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Live Attenuated Measles-Mumps-Rubella (MMR) Vaccine When Given to Healthy Children at the Age of 12 to 18 Months in Singapore.
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 150 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 12 Months – 18 Months
- Healthy volunteers
- Accepted
Summary
To evaluate the safety and immunogenicity of GSK Biologicals' live attenuated MMR vaccine (Priorix) in a local population in Singapore. The vaccine was administered as a single dose to healthy children (12-18 months of age) and blood samples were collected at two time points (before vaccination and after vaccination).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MMR vaccine (Priorix) |
Timeline
- Start date
- 2000-11-01
- Primary completion
- 2001-04-01
- Completion
- 2001-04-01
- First posted
- 2006-10-16
- Last updated
- 2016-09-20
Source: ClinicalTrials.gov record NCT00388440. Inclusion in this directory is not an endorsement.